Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1 (AMPACT1) – open-label extension to TACTT2
KCT0001511Phase 3Completed
- Sponsor
- Altamira Therapeutics
- Start
- Jul 2015
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of Keyzilen in tinnitus, sponsored by Altamira Therapeutics. Started Jul 2015; status: completed.
02
Drugs
Keyzilen
03
Conditions
tinnitus
Beyond the preview
Go deeper on KCT0001511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001511.